Chhattisgarh Civil Society (CCS) issued the notice to Navjot Kaur and her husband, Navjot Singh Sidhu for the claim that cancer can be cured with a diet containing lemonade, raw turmeric, and neem
In 2023, Dr Reddy's signed a licensing and commercialisation agreement with Shanghai Junshi Biosciences for Toripalimab
The Central Drugs Standard Control Organisation granted approval for the drug's use in combination with Durvalumab for the maintenance treatment of advanced or recurrent endometrial cancer in adults
Doctors, including the director of Tata Memorial Hospital, have refuted Sidhu's claim that his wife overcame cancer following a strict diet
The government has asked the companies to reduce prices of three anti-cancer drugs to pass on the benefit of customs duty exemption and GST reduction to the consumers. In line with the government's commitment to ensure the availability of drugs at affordable prices, the National Pharmaceutical Pricing Authority (NPPA) has issued an office memorandum directing the concerned manufacturers to reduce the MRP on three anti-cancer drugs, Trastuzumab, Osimertinib and Durvalumab. This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty, the Ministry of Chemicals and Fertilisers said in a statement. The Department of Revenue, Ministry of Finance, issued a notification dated July 23, this year reducing the customs duty to nil on the three drugs. "Accordingly, there should be a reduction in MRP of these drugs in the market and benefits of reduced taxes and duties should be passed on to the consumers,"
This works because cancers have fooled the body by using its own natural safety switches, or checkpoints
New cancer drugs launched each year increased from 0.5 in the 1990s to over eight in 2022 among high-income countries, whereas they increased from 0.1 to 1.5 a year among upper-middle-income countries, according to a global analysis revealing "significant" and "widening" disparities. New drug launches remained minimal in lower-middle-income and low-income countries, it found. Published in the British Medical Journal (BMJ) Global Health, the analysis highlighted significant disparities in both availability and timeliness of these medicines worldwide, according to researchers. The inequities could explain the poor cancer outcomes across many countries, especially the low- and middle-income ones, where mortality-to-incidence ratios have been studied to be higher, despite overall cases being lower, the researchers, including those from The Pennsylvania State University, US, said. The measure 'mortality-to-incidence ratio' is used to compare inequities in cancer outcomes. It is calculat
Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to produce a generic prostate cancer treatment drug. The company has received tentative approval from the US Food and Drug Administration (USFDA) to manufacture Enzalutamide tablets (40 mg and 80 mg), the drug maker said in a regulatory filing. Enzalutamide tablets are androgen receptor inhibitors indicated for the treatment of patients with castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer. The product would be manufactured at the Group's manufacturing site at SEZ, Ahmedabad. As per IQVIA MAT July 2024 data, Enzalutamide tablets (40 mg and 80 mg) had annual sales of USD 1,417.2 million in the US. The Zydus group now has 400 approvals and has so far filed over 465 Abbreviated New Drug Application (ANDAs) since the commencement of the filing process in FY 2003-04, it said.
Sun Pharmaceutical Industries on Tuesday said it has inked a global licensing pact with Italian-Swiss firm Philogen for an anti-cancer drug. As per the agreement, Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun, a speciality product of Philogen. Fibromun, an innovative anti-cancer immunotherapy, is being investigated in registration trials by Philogen for the treatment of soft tissue sarcoma and glioblastoma. As per the pact, Philogen will complete the ongoing pivotal clinical trials for the product, pursue marketing authorisation with regulatory authorities, and manufacture commercial supplies, the Mumbai-based drug major said in a statement. Sun Pharma will be responsible for commercialisation activities, it added. The two partner companies will share post-commercialisation economics in about 45(Philogen):55(Sun Pharma) ratio, Sun Pharma said. The company did not disclose other financial terms. "Fibromun's progress through development has been qui
The overall survival, or OS rates, in the TROPION-Breast01 Phase III trial of datopotamab deruxtecan (Dato-DXd), did not achieve statistical significance
Top Quad leaders will unveil a "milestone" initiative on Saturday to prevent, detect, treat and alleviate the impact of cancer on patients and their families, when they gather in Wilmington in the US for their annual summit. Being hosted by US President Joe Biden, the "Quad Leaders Summit" will be attended by Prime Minister Narendra Modi, his Australian counterpart Anthony Albanese and Japan's Fumio Kishida. The leaders are expected to deliberate on pressing global challenges, including the Russia-Ukraine conflict, escalating tensions in West Asia and the overall situation in the Indo-Pacific. At a media briefing on Modi's visit to the United States from September 21-23, Foreign Secretary Vikram Misri said the "signature" "Cancer Moonshot" event will take place on the sidelines of the Quad summit in Wilmington, Delaware. "One of the signature initiatives to be unveiled on the sidelines is the Cancer Moonshot event," he said. "Through this milestone initiative, the Quad aims to ...
AstraZeneca Plc and Daiichi's breast cancer drug Enhertu is based off of Daiichi's antibody-drug conjugate platform DXd, and was the top-selling ADC globally in 2023
First-in-human trial is a type of clinical trial in which a new drug, procedure or treatment is tested in humans for the first time
Move is part of ongoing initiatives to reduce financial burden for cancer patients
Key changes were proposed that could affect what consumers pay for certain goods and services. Here's what may get pricier and what might ease your wallet if the proposals are accepted
The companies collectively are facing thousands of lawsuits against them in courts across the United States
Lung cleansing, or lung detoxification, is said to be the process to clean the lungs of pollutants, toxins and mucus. Here's all you need to know about lung cleansing
The market for pharmaceutical products used in managing Covid-19 has shrunk by billions of dollars a year, including for Pfizer's vaccines and treatments
Around 26 per cent of cancer patients in India have tumours in the head and neck, and there is an upward trend of such cases in the country, a study has found. The findings of the study, conducted on 1,869 cancer patients across the country, were released on the World Head and Neck Cancer Day observed on Saturday. Cancer Mukt Bharat Foundation, a Delhi-based non-profit organisation, conducted the study by collating data from calls received on its helpline number from March 1 to June 30. Dr. Ashish Gupta, a senior oncologist who is heading the Cancer Mukt Bharat Campaign in India, said that India is seeing surge in head and neck cancer cases, especially among young men, due to increased tobacco consumption and human papillomavirus (HPV) infection. "Around 80-90 pc of oral cancer patients have been found to use tobacco in some form, be it smoking or chewing. Most of the head and neck cancer are preventable, unlike other cancers for which the reason is unknown. It is a preventable ..
The government makes all efforts to ensure affordable and accessible treatment is available for cancer patients amid a rise in cases in India, Health Minister JP Nadda said on Friday. Replying to supplementary questions during Question Hour in the Lok Sabha, Nadda said the government made all efforts to ensure that affordable and accessible treatment was available to the patients. "The number of cancer cases is going up, it is increasing by almost 2.5 per cent every year," Nadda said. In men, cases of oral and lung cancer are on the up while more women are getting breast cancer, he added. More than 15.5 lakh cancer cases are being registered every year, Nadda said. "There is a list of 131 essential cancer medicines, which are in Schedule 1, (that) are monitored and (their) pricing is decided by the government. These are the commonly used medicines," Nadda said. He said patients cumulatively saved around Rs 294 crore due to this price control. "There are 28 combinations, which ar